Rentaro Oda

Rentaro Oda

Auto-generated profile, based on publicly available information

Rentaro Oda

Division of Infectious Diseases, Musashino Red Cross Hospital, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JGJonathan Grein
Jonathan Grein
NONorio Ohmagari
Norio Ohmagari
DSDaniel Shin
Daniel Shin
GDGeorge Diaz
George Diaz
EAErika Asperges
Erika Asperges
TFTimothy Flanigan
Timothy Flanigan
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)

1 May 2017 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RORentaro Oda
Rentaro Oda
SKSatoshi Kutsuna
Satoshi Kutsuna
YSYoshiyuki Sekikawa
Yoshiyuki Sekikawa
IHIgen Hongo
Igen Hongo
KSKozue Sato
Kozue Sato
HKHiroki Kawabata
Hiroki Kawabata

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
RORentaro Oda
Rentaro Oda
YSYoshiyuki Sekikawa
Yoshiyuki Sekikawa
IHIgen Hongo
Igen Hongo

9 December 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
TNTakaya Namiki
Takaya Namiki
YYYuta Yokoyama
Yuta Yokoyama
HHHideki Hashi
Hideki Hashi
RORentaro Oda
Rentaro Oda
AJAya Jibiki
Aya Jibiki
TNTomonori Nakamura
Tomonori Nakamura
Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended‐spectrum β‐lactamase producing enterobacterales (ESBL‐E) and investigate optimal dosing regimens for not undergoing hemodialysis (non‐HD) and undergoing hemodialysis (HD) patients.Design: Prospective observational study.Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022.Measurements: Total and Unbound CMZ concentration was measured by high‐performance liquid chromatography (HPLC) with solid‐phase extraction and ultrafiltration.Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non‐HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre‐HD), and 1 and 3 h after starting HD and post‐HD. All blood samples were collected at steady‐state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non‐HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule.Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non‐HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non‐HD patients with an ESBL‐E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1‐ and 3‐h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL‐E MIC of 4 mg/L.Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL‐E‐infected patients.

11 May 2023 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SSSho Saito
Sho Saito
SKSatoshi Kutsuna
Satoshi Kutsuna
IAImamura Akifumi
Imamura Akifumi
RHRyota Hase
Ryota Hase
RORentaro Oda
Rentaro Oda
HMHiroaki Mitsuya
Hiroaki Mitsuya

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
PDF file
YSYoshiyuki Sekikawa
Yoshiyuki Sekikawa
RORentaro Oda
Rentaro Oda
IHIgen Hongo
Igen Hongo
EOEmi Ono
Emi Ono